



**PELVIC  
RADIATION  
DISEASE  
ASSOCIATION**



**Annual Report 2021-2022**

- 3** Legal & Administrative Information
- 3** Foreword
- 4** Introduction
- 5** About the PRDA, our aims and objectives
- 6-7** Highlights of 2021-2022
- 8** Our year in numbers
- 9** Patient stories
- 10** A summary of our plans for the year ahead
- 11-13** Report of the trustees
- 14-22** Financial review

## Legal & Administrative Information

**Registered Company number:** 07998409 (England and Wales)

**Registered Charity number:** 1147802

**Registered office:** 62 Norbiton Avenue, Kingston upon Thames, Surrey, KT1 3QP

**Chair:**

John A Webber

**Trustees:**

Alison S Boyes

David E Jillings

Dr Lisa A Punt

Dr Benjamin D Sacks

Bhumi Shah

Dr Lesley Smith

**Company Secretary:** D E Jillings

**Independent Examiner Details:**

Mary E Ryan

FCCA, CertPFS, DChA

Ark Accountancy, Chartered Certified Accountant, 31 Cheam Road Epsom Surrey, KT17 1QX

## Foreword

**Samantha Bostock**

In my role as a Late Effects Lead Radiographer, I have seen first-hand the incredibly debilitating impact Pelvic Radiation Disease can have on people in the months and years following radiotherapy for pelvic cancers. It can destroy quality of life due to the physical, emotional, and psychological impact of symptoms in so many ways – people are unable to leave their homes, work or continue relationships. Symptoms can be distressing and life-changing following cancer treatment – and often devastating in their severity.

The work of PRDA means that people feel less alone. The charity helps people to understand and take control of their symptoms and gives people the confidence to ask questions of their healthcare team. The work this charity does to raise awareness and support both people living with PRD and their carers is wide-ranging and invaluable. They give a voice to people with PRD.

Equally important is their work with health care professionals who work with people experiencing PRD to improve their symptoms and quality of life – not to mention those professionals who are unaware of PRD, which is a far greater number than we might like to think. PRDA's support is instrumental in building radiotherapy late effects services, and in developing the resources we need to ensure our patients receive the best care possible. It is vital that PRDA continue to receive support so they can build on the vital work they do in raising awareness of PRD and its management. I very much look forward to continuing to work with them over the coming year.



## Introduction

### John Webber - Chair of Trustees

In 2021/22, against the backdrop of the nation coming out of lockdown, PRDA continued to grow while putting into practice all we had learned during the coronavirus pandemic.

Being forced to move our support services online had been a revelation for the organisation, and we have continued to offer fully remote support to patients over the past year.

As ever, we have divided our focus into two key areas: direct patient support, and professional engagement.

Our online community and remote support offerings have continued to grow steadily, while our ground-breaking Out and About Toolkits, launched in December, have quickly become a cornerstone of our work.

Alongside our support offering, we have also launched our volunteering programme, and now have 14 volunteers. Most notably, we established our Patient Advisory Group – we thank them wholeheartedly for their feedback and consultancy throughout the year.

Our professional engagement programme has continued to build off of the successes of last year's Annual Conference, and we look forward to launching our new Best Practice Pathway later in 2022. This will be a pioneering piece of work and has taken huge effort from our Trustees Dr Lesley Smith and Dr Ben Sacks, alongside countless hours contributed by our network of health professionals. The document will be launched at our conference in the autumn and is set to be a ground-breaking moment for the organisation.

As ever, we are incredibly grateful to our supporters and donors for the contributions they have made to fund our critical work. As an organisation, we have grown our turnover year-on-year since our formation in 2012, and we now feel that we are uniquely well-placed to support people living with PRD. It is because of this that we feel a great responsibility to give a voice to people living with PRD, and we are now more dedicated and focused on these aims than ever.

Thank you.



we feel a great responsibility to give a voice to people living with PRD, and we are now more dedicated and focused on these aims than ever



## About the PRDA, our aims and objectives

The Pelvic Radiation Disease Association gives a voice to people affected by Pelvic Radiation Disease, an extremely debilitating condition caused by radiotherapy treatment for cancer in the pelvic area. By offering information, peer-to-peer support, and advocacy for patients, we improve quality of life for people who have been treated for cancer but are now living with the consequences.

We exist to help the estimated 100,000 people in the UK who had been hoping to get back to a normal life after cancer but are now living with PRD. The disease can destroy a patient's quality of life due to difficulties with bladder and bowel control, sexual function, fertility, and mobility, as well as social isolation and mental health issues.

### The key objectives and outcomes of our work are:

Outcome	Performance indicator
<b>Fewer people</b> feel alone while experiencing the debilitating symptoms of PRD	Increasing the number of patients engaging with our direct support offerings, including the Chat Together support groups, Online Community, and new one-to-one support pilot project.
<b>Better information</b> is made available to patients in advance of radiotherapy treatment	We are producing new literature for patients and will disseminate the most up to date PRDA information to as many people affected by PRD as possible.
<b>Better understanding among health professionals</b> who are treating people with PRD symptoms	Bringing together greater numbers of health professionals to engage in conversations about PRD, launching the Best Practice Pathway to the widest possible audience and seeing increased engagement with our resources for health professionals.
<b>Reduced stigma</b> associated with having long-term, embarrassing symptoms after cancer treatment	More usage of our Out and About Toolkits to give people more confidence in managing their symptoms, and access to patient stories and peer support to help people know they are not alone.
<b>Wider awareness of PRD</b> in the medical and research community and evidence of the need to conduct more research on how to prevent and treat PRD	Widening our corporate network of companies working in these fields, strengthening our relationships with other charities working in the sector, and growing our network of health professionals. Establishing Pelvic Radiation Disease as an accepted term and getting it included in data collected by clinics.
<b>Improved quality of life</b> for people affected by PRD.	Increased uptake of our support services. Regular discourse and consultation with our Patient Advisory Group in all areas of our work to ensure we are offering people affected by PRD the help they want and need.



### Growth of the volunteering programme and PAG

Since recruiting a Services and Volunteer Officer, we have been able to launch our volunteering programme and Patient Advisory Group quickly, and they are now central to our success. Our Patient Advisory Group now has eight members, and they feed into many areas of the organisation's work, to reflect the voice of people living with PRD. We thank them for their efforts over the past year.



### Out and About Toolkits

Our new Out and About Toolkits are filled with useful information, tips, and items to help people with PRD have more confidence when leaving the house – something which can be extremely challenging when struggling with PRD symptoms. We were thrilled to see our initial pilot run of 100 packs – funded by the National Lottery – run out within five weeks back in December 2021, and we are now planning to distribute another 300 packs before the end of the financial year.



### Professional engagement

The majority of our focus has been the production of the Best Practice Pathway for Pelvic Radiation Disease, a reference for any clinician who encounters PRD. In order to create this resource, we have been working closely with clinicians and academics up and down the country.

PRDA has also had abstracts and poster presentations accepted at clinical conferences. This is an excellent opportunity to meet and exchange ideas with others working in PRD.



### Growth of all platforms and service offerings

Our network of supporters, patients and professionals has continued to grow steadily as we expand our reach and diversify our work.

We have seen rises in all metrics across our online platforms and channels, and our Online Community and Chat Together groups are experiencing higher levels of engagement than ever. Our online community has grown to 297 members and has had an amazing 38,000 page views.

Visits to our website were up by 65% compared to the previous year and our social media followers have increased by 34% which we are really pleased to see. We are always looking for new ways to support people with PRD, and these channels are what allow us to do that.

### Surpassing income targets

Despite setting a higher target than ever before and forecasting an acceptable operational loss for the financial year, 2021/22 broke all records for income for PRDA. This was in large part due to a donation of £10,000 from Aspire Pharma, to help us fund our upcoming Best Practice Pathway and Annual Conference. We also saw record income from regular and individual donors, and we thank everyone who chose to contribute to PRDA in the last year.

### Operational improvements

Over the previous year we have made a number of important internal changes to improve our operational processes.



We now have three part-time members of **staff** covering three distinct areas of operation: Marketing and Communications, Fundraising and Events, and Services and Volunteering. As a result, we are expanding our work quicker than ever, and our staff can now focus more on their particular areas of work.



We have introduced a **Client Relationship Management** system to help us capture more and better data, which will inform our work in the future. While it can be a long process to introduce a new CRM, we are already noticing the benefits of more streamlined data capture.



Alongside the introduction of the CRM, we have also moved to **Microsoft 365** to enable better remote and asynchronous working. Since the pandemic, we have moved to a fully remote working process with members of our team and Board located in many different areas of the UK.

## Our year in numbers

Social media followers up **34%**



Over **350** professionals and patients attended our first digital Annual Conference



Over **11,000** visitors to our website

an increase of **65%**



**152** Out and About Toolkits provided



**27+** hours of sessions for our Chat Together service



**297** Online Community members



Our online community for people living with Pelvic Radiation Disease also had **38,000** page views



"The patient stories on the PRDA website have repeatedly reminded me that I'm not alone, and that I'm not imagining the symptoms I'm living with. Persistent pain without an obvious injury than can be seen is hard for people to understand, including in your own mind, and I've often wondered if I'm somehow making it worse than it really is."

### Rebecca's Story

I was diagnosed with colorectal cancer in March 2017 and 6 weeks of radiotherapy started in May of that year.

I was given the all-clear in 2018, from the colorectal cancer, but two weeks after that all-clear I was rushed into hospital with severe kidney pain, due to a blockage. The consultants then told me that I now had a life-long issue, because the radiotherapy had caused scar tissue in the ureter, between the kidney and the bladder.

Hearing the consultant say that the radiotherapy had caused the blockage really set me back.

PRD has such a varied number of symptoms. I've also had a kidney removed because of it. Generally, it's quite difficult; you can be on the toilet all day, or you can be in agony because you're not going for four or five days.

The biggest impact that PRD has had on me is the shock of being taken into hospital after being given the all-clear. When you realise that the radiotherapy has caused such serious issues, your mental health just plummets, because it's so unexpected.



**PRD is worse than the cancer, and I was totally unprepared for it.  
It's such a rollercoaster and just so unexpected.**

People do need to be aware, that, if there are issues, you can get help.

Finding PRDA made me feel so relieved. Suddenly, you've got a great big hug! It's not just you, there are other people like you. There's a group of people that know exactly what I'm going through. The PRDA want to help others; they want to educate health professionals.

My big message to other people who might be experiencing late effects symptoms – whether they have a PRD diagnosis or not – is that you are not alone.

## A summary of our plans for the year ahead

### Services

#### Let's Talk programme

In 2022 we received grant funding from the National Lottery Community Fund to set up a new programme to help people experiencing PRD for the first time to better understand their symptoms, and how to manage them.

### Volunteering

Continue to build the volunteering programme  
We will increase our range of opportunities to volunteers and develop our volunteer resources hub so we can better support the people who give up their time to support us.

### Professional engagement

#### Best Practice Pathway

We will launch a pioneering document outlining pathways of care for people with, or at risk of, PRD, that we have developed in conjunction with leading experts in the field of pelvic radiotherapy.

#### 2022 Annual Conference

The launch of the Best Practice Pathway will happen at our Annual Conference, as we bring together patients and professionals to discuss treatment and diagnosis of PRD.

### Awareness

#### Increasing reach

We will continue to focus on expanding our reach through social media and leaning on our partners to help us spread information about PRD further.

#### Better information

Our Best Practice Pathway for Pelvic Radiation Disease and its accompanying literature will help both healthcare professionals and people affected by PRD to better understand the condition and the care options available.

### Fundraising

#### Increasing and diversifying income

As an organisation we have grown our turnover steadily year-on-year since forming in 2012. Our focus is now to build a long-term, sustainable fundraising strategy that will allow us to scale up all our service offerings.



## PELVIC RADIATION DISEASE ASSOCIATION

### Report of the Trustees for the Year Ended 31 March 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### **OBJECTIVES AND ACTIVITIES**

##### **Objectives and aims**

The term Pelvic Radiation Disease is still to gain general acceptance among health professionals as a valid and useful framework within which to describe brief or long lasting problems, mostly in the bowel, caused by pelvic radiotherapy. The trustees aim to bring this disease to the attention of health professionals and patients to inform them about how to alleviate their symptoms. The trustees work to have the most up to date information for patients on the various aspects of Pelvic Radiation Disease and available resources for treatment.

The objectives of the charity as per the Articles are:

To campaign for the wider recognition of Pelvic Radiation Disease as well as for improvement in National Health Service facilities and treatment to help the management of radiation induced injury.

To support patients suffering from radiation induced injury and in particular patients suffering from Pelvic Radiation Disease in any appropriate way including through a network of informal support groups that are professionally supported.

To gather information about and support research into Pelvic Radiation Disease.

##### **Significant activities**

Founded thirteen years ago as a patient support group and registered as a charity in 2012, the trustees continue to dedicate themselves, with the support of volunteers, to expand the outreach of the Pelvic Radiation Disease Association (PRDA) and to further refine the charity's provision of information, support and guidelines to both patients and health professionals.

#### **FINANCIAL REVIEW**

The year started with an ambitious spending target and the possibility of a small and acceptable operating loss over the period. Fundraising managed to exceed expectations and match spending, resulting in a year with a record turnover by some considerable margin but also a small increase in funds in the bank.

##### **Financial Position**

The gross income of the charity for the year ended 31 March 2022 amounted to £41,399 (2020/21: £28,391) whereas costs for charitable activities were £38,018 (2020/21: £30,938), of which Governance costs were £640 (2020/21: £620). The net surplus for the year was £3,381 (2020/21: deficit £2,547).

The overall net assets of the company have increased from £42,049 to £45,430.

##### **Reserves policy**

It is the policy of the trustees to maintain unrestricted funds, which are the free reserves of the charity, at the minimum level of £10,000.

## PELVIC RADIATION DISEASE ASSOCIATION

### Report of the Trustees for the Year Ended 31 March 2022

#### **STRUCTURE, GOVERNANCE AND MANAGEMENT**

##### **Governing document**

The Charity was established under a Memorandum of Association which established the objects of the charitable company, and is governed under its Articles of Association.

The charity is governed by the Board of trustees, which meets on a regular basis. The secretary and the trustees manage all day to day operations of the charity and support and advise on all financial matters.

The charity is registered with the Fundraising Regulator

##### **Recruitment and appointment of new trustees**

Trustees receive written minutes at Board Meetings held during the year to ensure they are kept up to date with the activities of the charity. In addition, the trustees review The Pelvic Radiation Disease Association portfolio of policies and procedures on a regular basis, and introduce new policies and procedures as appropriate.

Mr Willie Auld resigned as a trustee 20/12/2021.

##### **Related parties**

The Charity has no subsidiaries. There are no related parties in the charity.

##### **Risk management**

The trustees have assessed the major risks to which the Charity is exposed, in particular those related to the operation and finances of the charity, and are satisfied that the systems are in place to mitigate their exposure to the major risks. Efforts are continuously made to increase funds. Internal risks are minimized by implementation of satisfactory operational procedures, and consistent quality of service delivery. These are reviewed by the Board on a regular basis.

PRDA does not hold any investments.

#### **REFERENCE AND ADMINISTRATIVE DETAILS**

##### **Registered Company number**

07998409 (England and Wales)

##### **Registered Charity number**

1147802

##### **Registered office**

62 Norbiton Avenue  
Kingston upon Thames  
Surrey  
KT1 3QP

##### **Trustees**

W Auld (resigned 20.12.21)  
D E Jillings  
Dr L A Punt  
Dr B D Sacks  
B K Shah  
Dr L M Smith  
J A Webber (Chair)  
Ms A S Boyes

##### **Company Secretary**

D E Jillings

PELVIC RADIATION DISEASE ASSOCIATION

Report of the Trustees  
for the Year Ended 31 March 2022

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Independent Examiner**

Mary E Ryan  
FCCA, CertPFS, DChA  
Ark Accountancy  
Chartered Certified Accountant  
31 Cheam Road  
Epsom  
Surrey  
KT17 1QX

Approved by order of the board of trustees on 12 August 2022 and signed on its behalf by:



D E Jillings - Trustee



Independent Examiner's Report to the Trustees of  
PELVIC RADIATION DISEASE ASSOCIATION

**Independent examiner's report to the trustees of PELVIC RADIATION DISEASE ASSOCIATION ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2022.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Mary E Ryan*

Mary E Ryan  
FCCA, CertPFS, DChA  
Ark Accountancy  
Chartered Certified Accountant  
31 Cheam Road  
Epsom  
Surrey  
KT17 1QX

Date: .....

*31/10/22*

# PELVIC RADIATION DISEASE ASSOCIATION

## Statement of Financial Activities for the Year Ended 31 March 2022

	Notes	Unrestricted fund £	Restricted fund £	31.3.22 Total funds £	31.3.21 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		7,829	-	7,829	6,362
<b>Charitable activities</b>					
Penguins against cancer		5,000	-	5,000	-
Dawnie Trust		1,000	-	1,000	-
P F Trust		-	-	-	3,000
Gisella Graham Foundation		1,000	-	1,000	1,000
National Lottery Community Fund		-	-	-	4,400
The Woodroffe Benton Foundation		-	-	-	500
Lennox Hannay Charitable Trust		-	-	-	1,000
National Lottery Local Community Fund		-	-	-	2,486
Hospital Saturday Fund		2,000	-	2,000	-
Community Fund Local Connect		-	2,450	2,450	-
Aspire Pharma		10,000	-	10,000	-
Other trading activities	2	<u>12,120</u>	<u>-</u>	<u>12,120</u>	<u>9,643</u>
<b>Total</b>		<b>38,949</b>	<b>2,450</b>	<b>41,399</b>	<b>28,391</b>
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Charitable activities		32,671	-	32,671	30,938
Lennox Hannay Charitable Trust		-	1,795	1,795	-
Community Fund Local Connect		-	3,552	3,552	-
<b>Total</b>		<u>32,671</u>	<u>5,347</u>	<u>38,018</u>	<u>30,938</u>
<b>NET INCOME/(EXPENDITURE)</b>		<b>6,278</b>	<b>(2,897)</b>	<b>3,381</b>	<b>(2,547)</b>
<b>Transfers between funds</b>	10	<u>4,413</u>	<u>(4,413)</u>	<u>-</u>	<u>-</u>
<b>Net movement in funds</b>		<b>10,691</b>	<b>(7,310)</b>	<b>3,381</b>	<b>(2,547)</b>
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<u>34,739</u>	<u>7,310</u>	<u>42,049</u>	<u>44,596</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u><b>45,430</b></u>	<u><b>-</b></u>	<u><b>45,430</b></u>	<u><b>42,049</b></u>

The notes form part of these financial statements

PELVIC RADIATION DISEASE ASSOCIATION

Balance Sheet  
31 March 2022

	Notes	Unrestricted fund £	Restricted fund £	31.3.22 Total funds £	31.3.21 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	8	150	-	150	100
Cash at bank		<u>47,398</u>	<u>207</u>	<u>47,605</u>	<u>44,528</u>
		47,548	207	47,755	44,628
<b>CREDITORS</b>					
Amounts falling due within one year	9	(2,118)	(207)	(2,325)	(2,579)
		<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
<b>NET CURRENT ASSETS</b>		<u>45,430</u>	<u>-</u>	<u>45,430</u>	<u>42,049</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
		<u>45,430</u>	<u>-</u>	<u>45,430</u>	<u>42,049</u>
<b>NET ASSETS</b>		<u>45,430</u>	<u>-</u>	<u>45,430</u>	<u>42,049</u>
<b>FUNDS</b>					
Unrestricted funds	10			45,430	34,739
Restricted funds				<u>-</u>	<u>7,310</u>
<b>TOTAL FUNDS</b>				<u>45,430</u>	<u>42,049</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

PELVIC RADIATION DISEASE ASSOCIATION

Balance Sheet - continued

31 March 2022

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 12 August 2022 and were signed on its behalf by:



D E Jillings - Trustee



J A Webber - Trustee

Notes to the Financial Statements  
for the Year Ended 31 March 2022

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Website - 33% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**Pension costs and other post-retirement benefits**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**2. OTHER TRADING ACTIVITIES**

	31.3.22	31.3.21
	£	£
Fundraising events	11,814	7,368
Other income	<u>306</u>	<u>2,275</u>
	<u>12,120</u>	<u>9,643</u>

continued...



PELVIC RADIATION DISEASE ASSOCIATION

Notes to the Financial Statements - continued  
for the Year Ended 31 March 2022

**3. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	31.3.22	31.3.21
	£	£
Depreciation - owned assets	<u>-</u>	<u>3,142</u>

**4. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 March 2022 nor for the year ended 31 March 2021.

**Trustees' expenses**

There no trustees' expenses paid to the trustees in their role as trustees for the year ended 31 March 2022 nor for the year ended 31 March 2021

**5. STAFF COSTS**

The average monthly number of employees during the year was as follows:

	31.3.22	31.3.21
	<u>1</u>	<u>1</u>
Administrator		

No employees received emoluments in excess of £60,000.

**6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	6,362	-	6,362
<b>Charitable activities</b>			
P F Trust	3,000	-	3,000
Gisella Graham Foundation	1,000	-	1,000
National Lottery Community Fund	-	4,400	4,400
The Woodroffe Benton Foundation	500	-	500
Lennox Hannay Charitable Trust	-	1,000	1,000
National Lottery Local Community Fund	-	2,486	2,486
Other trading activities	<u>9,643</u>	<u>-</u>	<u>9,643</u>
<b>Total</b>	20,505	7,886	28,391
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Charitable activities	<u>23,788</u>	<u>7,150</u>	<u>30,938</u>
<b>NET INCOME/(EXPENDITURE)</b>	(3,283)	736	(2,547)

continued...

**PELVIC RADIATION DISEASE ASSOCIATION**

Notes to the Financial Statements - continued  
for the Year Ended 31 March 2022

**6. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	38,022	6,574	44,596
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>34,739</u>	<u>7,310</u>	<u>42,049</u>

**7. TANGIBLE FIXED ASSETS**

	Website £
<b>COST</b>	
At 1 April 2021 and 31 March 2022	<u>12,792</u>
<b>DEPRECIATION</b>	
At 1 April 2021 and 31 March 2022	<u>12,792</u>
<b>NET BOOK VALUE</b>	
At 31 March 2022	<u>-</u>
At 31 March 2021	<u>-</u>

**8. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.3.22 £	31.3.21 £
Tax	<u>150</u>	<u>100</u>

**9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.3.22 £	31.3.21 £
Social security and other taxes	(538)	61
Other creditors	2,223	1,898
Accrued expenses	<u>640</u>	<u>620</u>
	<u>2,325</u>	<u>2,579</u>

**10. MOVEMENT IN FUNDS**

	At 1.4.21 £	Net movement in funds £	Transfers between funds £	At 31.3.22 £
<b>Unrestricted funds</b>				
General fund	34,739	6,278	4,413	45,430
<b>Restricted funds</b>				
Restricted funds	7,310	(2,897)	(4,413)	-
	<hr/>	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>42,049</u>	<u>3,381</u>	<u>-</u>	<u>45,430</u>

continued...

Notes to the Financial Statements - continued  
for the Year Ended 31 March 2022

**10. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	38,949	(32,671)	6,278
<b>Restricted funds</b>			
Restricted funds	2,450	(5,347)	(2,897)
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>41,399</u>	<u>(38,018)</u>	<u>3,381</u>

**Comparatives for movement in funds**

	At 1.4.20 £	Net movement in funds £	At 31.3.21 £
<b>Unrestricted funds</b>			
General fund	38,022	(3,283)	34,739
<b>Restricted funds</b>			
Restricted funds	6,574	736	7,310
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>44,596</u>	<u>(2,547)</u>	<u>42,049</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	20,505	(23,788)	(3,283)
<b>Restricted funds</b>			
Restricted funds	7,886	(7,150)	736
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>28,391</u>	<u>(30,938)</u>	<u>(2,547)</u>

continued...

Notes to the Financial Statements - continued  
for the Year Ended 31 March 2022

10. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.4.20 £	Net movement in funds £	Transfers between funds £	At 31.3.22 £
<b>Unrestricted funds</b>				
General fund	38,022	2,995	4,413	45,430
<b>Restricted funds</b>				
Restricted funds	6,574	(2,161)	(4,413)	-
	<hr/>	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>44,596</u>	<u>834</u>	<u>-</u>	<u>45,430</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	59,454	(56,459)	2,995
<b>Restricted funds</b>			
Restricted funds	10,336	(12,497)	(2,161)
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>69,790</u>	<u>(68,956)</u>	<u>834</u>

11. RELATED PARTY DISCLOSURES

Expenses of £2,558 were reimbursed to 1 director during the year (2021 £1,826 to 4 directors)

PELVIC RADIATION DISEASE ASSOCIATION

Detailed Statement of Financial Activities  
for the Year Ended 31 March 2022

	31.3.22 £	31.3.21 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	5,390	4,918
Gift aid	<u>2,439</u>	<u>1,444</u>
	7,829	6,362
<b>Other trading activities</b>		
Fundraising events	11,814	7,368
Other income	<u>306</u>	<u>2,275</u>
	12,120	9,643
<b>Charitable activities</b>		
Grants	<u>21,450</u>	<u>12,386</u>
<b>Total incoming resources</b>	41,399	28,391
<b>EXPENDITURE</b>		
<b>Charitable activities</b>		
Wages	24,290	15,515
Pensions	229	52
Insurance	425	415
Telephone	531	448
Postage & stationery	158	1,548
Leaflets and posters	445	-
Sundries	258	429
Subscriptions & registrations	85	98
Fundraising	-	857
Payroll & HR	144	144
IT & website	2,688	1,232
Consultancy	3,605	4,305
Training	-	2,133
Conferences	968	-
O&A Toolkit	3,552	-
Dep'n of website	<u>-</u>	<u>3,142</u>
	37,378	30,318
<b>Support costs</b>		
<b>Governance costs</b>		
Accountancy fees	<u>640</u>	<u>620</u>
<b>Total resources expended</b>	<u>38,018</u>	<u>30,938</u>
<b>Net income/(expenditure)</b>	<u><u>3,381</u></u>	<u><u>(2,547)</u></u>

This page does not form part of the statutory financial statements



# Treated for cancer & living with the consequences?



We give a voice to people affected by Pelvic Radiation Disease



website | [prda.org.uk](http://prda.org.uk)  
office | 0113 278 5405  
email | [info@prda.org.uk](mailto:info@prda.org.uk)



#PelvicRadiationDisease

November 2022